Okanagan Clinical Trials part of global study for new Alzheimer’s treatment
Okanagan Clinical Trials is seeking volunteers to be involved in a study of a potential new treatment for Alzheimer’s disease.
The Kelowna-based company is part of a global effort to see if semaglutide, an oral medication used primarily for treating Type 2 Diabetes, could help with the neuro-degenerative disease.
“It’s already available in Canada and many people take it, and what they found while testing this medication on people with Type 2 Diabetes, when they looked back on all the research they did, they noticed that the instances of people with Alzheimer’s like dementia decreased in the people that were taking the medication,” said Dr. Kim Christie, President of Okanagan Clinical Trials.
“So, what we need to do now is run a new set of clinical research studies specifically on people with Alzheimer’s disease using this medication to see ‘does it actually change their cognitive outlook over the trajectory of the disease?”











